Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Acetylation
Animals
Benzamides
/ chemistry
Binding Sites
Charcot-Marie-Tooth Disease
/ drug therapy
Crystallography, X-Ray
Disease Models, Animal
Half-Life
Histone Deacetylase 6
/ antagonists & inhibitors
Histone Deacetylase Inhibitors
/ chemistry
Humans
Male
Mice
Mice, Inbred C57BL
Molecular Docking Simulation
Phenotype
Protein Isoforms
/ antagonists & inhibitors
Quinolines
/ chemistry
Structure-Activity Relationship
Tubulin
/ metabolism
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
22 04 2021
22 04 2021
Historique:
pubmed:
9
4
2021
medline:
16
6
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (
Identifiants
pubmed: 33830764
doi: 10.1021/acs.jmedchem.0c02210
doi:
Substances chimiques
Benzamides
0
Histone Deacetylase Inhibitors
0
Protein Isoforms
0
Quinolines
0
SW-100
0
Tubulin
0
1,2,3,4-tetrahydroquinoline
CCR50N1Z9G
Histone Deacetylase 6
EC 3.5.1.98
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4810-4840Subventions
Organisme : NINDS NIH HHS
ID : R01 NS079183
Pays : United States
Organisme : NICHD NIH HHS
ID : R43 HD093464
Pays : United States
Organisme : NIA NIH HHS
ID : R41 AG058283
Pays : United States